TFPI-2与VEGF在胰腺癌中的表达

目的:探讨胰腺癌中TFPI-2表达对胰腺癌肿瘤血管生成的影响。方法:采用免疫组织化学方法检测41例胰腺癌组织中TFPI-2、VEGF的表达及CD34单克隆抗体标记的微血管密度(MVD)。结果:Ⅰ、Ⅱ期胰腺癌及无远处转移的胰腺癌组织中TFPI-2阳性表达率分别为65.4%和57.1%,Ⅲ、Ⅳ期及有远处转移的胰腺癌组织中的TFPI-2阳性表达率分别为13.3%和23.1%,TFPI-2表达率,Ⅰ、Ⅱ期高于Ⅲ、Ⅳ期,无远处转移高于有远处转移,差异有统计学意义(P<0.05);VEGF阳性表达率在Ⅰ、Ⅱ期及无远处转移的胰腺癌组织分别为23.0%和32.1%,在Ⅲ、Ⅳ期及有远处转移的胰腺癌组织分别为66.7%和61.5%,两者比较,差异有统计学意义(P<0.05);Ⅲ、Ⅳ期及有远处转移的胰腺癌组织MVD值分别为28.47±2.23和19.00±2.58,高于Ⅰ、Ⅱ期的26.92±1.06及无远处转移的16.68±1.79,差异有统计学意义(P<0.05);胰腺癌组织中的TFPI-2的表达与VEGF的表达呈负相关(r=-0.54),差异有统计学意义(P<0.05);MVD与TFPI-2表达有关,TFPI-2阳性表达的胰腺癌组织MVD值为33.33±3.23,低于TFPI-2阴性表达的胰腺癌组织36.00±3.17,两者比较,差异有统计学意义(P<0.05)。结论:胰腺癌中TFPI-2可能通过下调VEGF的表达抑制肿瘤新生血管的形成,从而抑制胰腺癌的生长、转移。

Expression of TFPI-2 and VEGF in Pancreatic Carcinoma Angiogenesis

Objective: To explore the effect of tissue factor pathway inhibitor- 2 (TFPI- 2) expression on the angiogenesis of pancreatic carcinoma. Methods: Immunohistochemistry was employed to detect the expression of TFPI- 2 and VEGF and MVD was assessed with CD34 in 41 cases of pancreatic carcinoma. Results: The expression rate of TFPI- 2 in pancreatic carcinoma of stage Ⅰ and Ⅱ was 65.4%, higher than that of stage Ⅲ and Ⅳ (13.3%), with a significant difference (P<0.05). The expression rate of TFPI- 2 in pancreatic carcinoma without distant metastasis was 57.1%, higher than that found in cases of pancreatic carcinoma with distant metastasis(23.1%), with a significant difference(P<0.05). The expression rate of VEGF was 23.0% in pancreatic carcinoma of stage Ⅰ and Ⅱ and 32.1%in pancreatic carcinoma without distant metastasis, both lower than that of stage Ⅲ and Ⅳ (66.7%) and pancreatic carcinoma with distant metastasis (61.5%). The difference was significant (P<0.05). The expression of TFPI- 2 and VEGF was negatively correlated (r=- 0.54, P<0.05). MVD was correlated with TFPI- 2 expression. The value of MVD in the group with TFPI- 2 expression (33.33± 3.23) was lower than that in the group without TFPI- 2 expression(36.00± 3.17, P<0.05). Conclusion: TFPI- 2 may inhibit the angiogenesis of pancreatic carcinoma by reducing the expression of VEGF. Understanding its role can help prevent invasion and metastasis of pancreatic carcinoma.